QUANTIFY CANCER
De-risk and accelerate your drug approval with
ctDNA-based MRD and response
monitoring
Guardant Infinity can help bring effective new cancer therapeutics to patients—faster.
Enrich clinical trial populations to decrease
trial size and accelerate patient enrollment¹
Gain early insights into therapy response²
Develop a surrogate endpoint or determine dosing with ctDNA reduction or clearance³
ctDNA, circulating tumor DNA; MRD, minimal residual disease.
Home Guardant Infinity™ for BioPharma Guardant360® CDx for BioPharma GuardantINFORM for BioPharma